2N Pharma AB was incorporated in Sweden today to build on a decade of John Nieland’s research in neurological disorders. This marks the formal beginning of the process to take potential therapies from preclinical results to humans. With an experienced management team that has done it before, we are looking forward to the challenges ahead.